Wall Street Zen upgraded shares of Promis Neurosciences (NASDAQ:PMN – Free Report) from a sell rating to a hold rating in a research report report published on Saturday,Wall Street Zen reports.
A number of other analysts have also recently commented on PMN. Guggenheim reiterated a “buy” rating and issued a $69.00 target price (up from $35.00) on shares of Promis Neurosciences in a research note on Tuesday, July 28th. Chardan Capital set a $20.00 price target on shares of Promis Neurosciences and gave the company a “buy” rating in a research note on Monday, July 27th. Roth Capital decreased their price target on shares of Promis Neurosciences to $15.00 and set a “buy” rating for the company in a report on Monday, November 2nd. HC Wainwright reaffirmed a “buy” rating on shares of Promis Neurosciences in a report on Monday, October 12th. Finally, Weiss Ratings upgraded shares of Promis Neurosciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, November 2nd. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Promis Neurosciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $30.50.
Get Our Latest Report on Promis Neurosciences
Promis Neurosciences Price Performance
Promis Neurosciences (NASDAQ:PMN – Get Free Report) last issued its quarterly earnings results on Thursday, November 12th. The company reported ($0.89) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.28) by $0.39. As a group, equities research analysts forecast that Promis Neurosciences will post -5.07 earnings per share for the current fiscal year.
Insider Buying and Selling at Promis Neurosciences
In other Promis Neurosciences news, Director Eugene Williams purchased 26,500 shares of the stock in a transaction on Wednesday, November 4th. The shares were bought at an average cost of $3.43 per share, with a total value of $90,895.00. Following the completion of the acquisition, the director owned 40,213 shares in the company, valued at $137,930.59. This trade represents a 193.25% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Neil Cashman purchased 10,000 shares of the business’s stock in a transaction on Monday, November 2nd. The shares were bought at an average cost of $3.86 per share, for a total transaction of $38,600.00. Following the completion of the transaction, the insider directly owned 14,532 shares in the company, valued at $56,093.52. This trade represents a 220.65% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders acquired 37,816 shares of company stock worth $134,746. 1.50% of the stock is owned by corporate insiders.
Institutional Trading of Promis Neurosciences
A number of hedge funds have recently modified their holdings of PMN. Seven Fleet Capital Management LP acquired a new stake in Promis Neurosciences during the first quarter worth about $135,000. ADAR1 Capital Management LLC acquired a new position in Promis Neurosciences in the first quarter valued at approximately $1,211,000. Yu Fan acquired a new position in Promis Neurosciences in the first quarter valued at approximately $4,188,000. Ally Bridge Group NY LLC lifted its holdings in Promis Neurosciences by 66.1% in the first quarter. Ally Bridge Group NY LLC now owns 414,219 shares of the company’s stock valued at $5,261,000 after acquiring an additional 164,880 shares during the period. Finally, Janus Henderson Group PLC purchased a new stake in Promis Neurosciences in the 1st quarter worth approximately $16,418,000. Hedge funds and other institutional investors own 50.13% of the company’s stock.
About Promis Neurosciences
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company developing antibody-based treatments for neurodegenerative diseases. Its research focuses on misfolded proteins that may contribute to these conditions. The company’s technology is designed to identify disease-associated forms of proteins while distinguishing them from their normally functioning counterparts. Its lead program, PMN310, is an antibody candidate targeting toxic amyloid-beta oligomers for the potential treatment of Alzheimer’s disease.
Further Reading
- Five stocks we like better than Promis Neurosciences
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Promis Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Promis Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.
